Biomedical Advanced Research and Development Authority

Error creating thumbnail:

Barda Logo

Biomedical Advanced Research and Development Authority (BARDA) is a U.S. government agency under the Department of Health and Human Services (HHS). It was established to aid in the development and procurement of necessary medical countermeasures (MCMs), such as vaccines, drugs, and diagnostic tools, against a wide range of public health emergencies, including infectious diseases, chemical, biological, radiological, and nuclear (CBRN) threats.

Overview

BARDA plays a critical role in the Public Health Emergency Preparedness framework by bridging the gap between the discovery of potential medical countermeasures and their development, manufacturing, and deployment. The agency operates by partnering with the private sector, academia, and other government agencies to accelerate the development of critical MCMs. Its approach includes funding research and development (R&D), providing technical assistance, and ensuring the availability of advanced manufacturing capabilities.

History

Established by the Pandemic and All-Hazards Preparedness Act (PAHPA) in 2006, BARDA was created in response to the recognized need for a more coordinated and agile response to emerging health threats. The agency's formation marked a significant shift towards enhancing the nation's preparedness and response capabilities against a broad spectrum of public health emergencies.

Key Functions

BARDA's key functions include:

• Funding and Supporting R&D: BARDA invests in the advanced research and development of innovative MCMs. This includes support for early-stage research, clinical trials, and the scaling up of manufacturing processes.
• Strategic National Stockpile (SNS): In collaboration with the Centers for Disease Control and Prevention (CDC), BARDA helps to manage the SNS, a national repository of antibiotics, vaccines, chemical antidotes, antitoxins, and other critical medical supplies.
• Innovation and Partnerships: The agency fosters innovation through public-private partnerships, engaging with biotechnology and pharmaceutical companies, universities, and other research institutions.
• Project BioShield: BARDA administers Project BioShield, a program aimed at acquiring and developing MCMs for use against CBRN threats.

Impact

BARDA's work has been instrumental in advancing the development and availability of MCMs for a variety of threats. Notably, the agency has played a pivotal role in responding to the H1N1 influenza pandemic, the Ebola and Zika virus outbreaks, and the COVID-19 pandemic. Through its efforts, BARDA has significantly contributed to enhancing the nation's preparedness and ability to respond to public health emergencies.

Challenges and Future Directions

Despite its successes, BARDA faces ongoing challenges, including the need for sustained funding, the management of complex partnerships, and the continuous evolution of global health threats. Looking forward, the agency aims to further innovate its approaches to MCM development, enhance its partnerships, and strengthen the public health emergency response infrastructure.